NYSE:AKER
Delisted
Akers Biosciences Inc Stock News
$3.81
+0 (+0%)
At Close: Jul 20, 2022
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
12:30pm, Friday, 16'th Apr 2021
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations
03:31pm, Friday, 12'th Mar 2021
NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights
Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers
01:25pm, Tuesday, 23'rd Feb 2021
Akers Biosciences Inc (NASDAQ: AKER) and its proposed merger partner MyMD Pharmaceuticals Inc have announced new data for MYMD-1 from the Eurofins Discovery Phenotypic Center of Excellence study
Akers Biosciences Responds to Erroneous Earnings Call Press Release
01:45pm, Wednesday, 17'th Feb 2021
NEW YORK--(BUSINESS WIRE)--Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a c
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - AKER, INFO, SNSS, WORK, WDR
04:55pm, Saturday, 19'th Dec 2020
NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Akers Biosciences, Inc. (NASDAQ: AKER) concerning po
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Akers Bios
Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent
09:00am, Wednesday, 02'nd Dec 2020
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”) was issued US Pat. No. 10,835,523 B2, title
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Akers Biosciences, Inc. - AKER
04:51pm, Wednesday, 18'th Nov 2020
NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York C
REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals
08:00am, Wednesday, 18'th Nov 2020
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to ho
SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc.
09:38pm, Thursday, 12'th Nov 2020
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akers Biosciences, Inc. ("Akers" or t
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Akers Biosciences, Inc.
03:21pm, Thursday, 12'th Nov 2020
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Akers Biosciences, Inc. (NASDAQ: AKER) and its board of directors concerning the propose
Wall Street Breakfast: What Moved Markets
02:01pm, Saturday, 29'th Aug 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12:00pm, Tuesday, 11'th Aug 2020
Thorofare, New Jersey, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several institu
Candriam Luxembourg S.C.A. Boosts Stake in Akers Biosciences Inc (NASDAQ:AKER)
06:56am, Sunday, 02'nd Aug 2020
Candriam Luxembourg S.C.A. increased its stake in shares of Akers Biosciences Inc (NASDAQ:AKER) by 123.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 36
Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies
01:00pm, Tuesday, 07'th Jul 2020
Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, the initiation of animal studies for its SAR